In a clinical trial of TNF‐α inhibitors (certolizumab, infliximab) combined with ICIs for melanoma, the ORR reached 100% in 7 patients receiving certolizumab combination therapy and 50% in 6 patients treated with infliximab combination therapy (NCT03293784).156. The gene discussed is TNF; the disease is melanoma.